Designed hybrid anticancer nuclear-localized peptide inhibits aggressive cancer cell proliferation

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• Cell proliferation is tightly regulated by the cell cycle, involving key proteins like p16.
• Inactivation of p16 protein contributes to uncontrolled cancer cell division and proliferation.
• Restoring p16 activity is a therapeutic strategy for various cancers.

Purpose of the Study:

• To enhance the efficiency and bioavailability of the p16 peptide for leukemia treatment.
• To develop a novel therapeutic agent targeting chronic myelogenous leukemia (CML) cells.
• To investigate the mechanism of a modified p16 peptide in inducing cancer cell apoptosis.

Main Methods:

• Conjugation of a nuclear-localized signal (NLS) sequence and an AVPI peptide to the p16 peptide.
• Design of a hybrid peptide targeting both nuclear and cellular factors in CML cells.
• Assessment of the peptide's effect on cell proliferation and apoptosis pathways.

Main Results:

• The NLS-attached hybrid peptide effectively targets human chronic myelogenous leukemia (CML) cells with lower p16 and higher XIAP expression.
• The peptide inhibits CML cell proliferation by targeting nuclear factors (CDK4/cyclin D) and cellular factor XIAP.
• The engineered peptide promotes a caspase-3 dependent apoptosis pathway, leading to cancer cell death.

Conclusions:

• The developed NLS-hybrid peptide is a promising anti-leukemia therapeutic agent.
• Targeting both nuclear and cellular factors offers a novel strategy for cancer treatment.
• Restoring p16 function via peptide modification can effectively suppress cancer progression.